|
Patent landscape, scope, and claims: |
US Patent 8,349,869: What Is the Scope of the Claims and How Broad Is the Patent Landscape?
What does US 8,349,869 claim, at a structural level?
US 8,349,869 is a composition-of-matter patent centered on a large, macrocyclic core (“formula (I)”) with extensive variable substitution. Claim 1 defines the legal scope as a compound family rather than a single molecule.
Core claim (Claim 1) scope
- Claim object: “A compound of formula (I)” that can be:
- an N-oxide
- a pharmaceutically acceptable salt
- a stereoisomer
- Double-bond optionality: dashed lines indicate optional double bonds in the macrocycle (each dashed line corresponds to an optional C=C feature).
- Key position variables: the molecule is defined through substituent positions X, R1-R8, and n.
Position definitions that drive breadth
- X
- X is N or CH
- if X “bears a double bond,” the corresponding atom is C (drives alkene placement).
- R1
- —OR7 (ether/alkoxy form)
- or —NH—SO2R8 (sulfonamide form)
- R2
- hydrogen
- and where X is C or CH, R2 may also be C1-6 alkyl
- R3
- hydrogen
- C1-6 alkyl
- C1-6alkoxyC1-6alkyl
- C3-7 cycloalkyl
- R4
- n
- 3, 4, 5, or 6 (macrocycle ring size variation)
- R5
- halo or C1-6 alkyl
- hydroxy
- polyhaloC1-6alkyl
- phenyl
- or Het
- R6
- C1-6 alkoxy or dimethylamino
- R7
- hydrogen, aryl, Het, or a cycloalkyl/alkyl-with-cycloalkyl substitution pattern (optionally substituted)
- R8
- aryl or Het, or substituted cycloalkyl/alkyl-with-heteroaryl substitution pattern (optionally substituted)
Terminal group and ring substituent breadth
- Phenyl substituent rule (for aryl groups):
- phenyl optionally substituted with 1 to 3 substituents selected from a long list (halo, hydroxy, nitro, cyano, carboxyl, alkyl, alkoxy, alkylcarbonyl, amino, dialkylamino, azido, mercapto, polyhalo alkyl/alkoxy, cycloalkyl, and piperazine/piperidine/morpholine-type substituents).
- Het definition:
- a 5- or 6-membered saturated/partially unsaturated/completely unsaturated heterocycle with 1 to 4 heteroatoms chosen from N/O/S
- may be optionally connected with a benzene ring (fused option)
- Het can also have 1 to 3 additional substituents from the same broad substituent set.
Specialization claims narrow a subset
- Claim 2 requires the compound to match one of formulas (I-c), (I-d), or (I-e).
- Claims 3, 4, 5, 6, 7, 8-15 specify further parameter selections (e.g., R4 fixed to specific rings; R5 and R6 fixed to enumerated groups; n fixed to 4 or 4/5; R1 fixed to ether or sulfonamide with enumerated R8).
What are the explicit claim dependences that tighten scope (and by how much)?
Claims 1-22 define the genus. Claims 2-22 add constraints that create narrower sub-genuses, but the legal coverage remains dominated by the wide genus of Claim 1.
Below is what the dependent claims do, using only the text provided.
| Claim |
What it narrows |
Examples from the claim text |
| 2 |
Constrains to specific sub-formulas |
“formula (I-c), (I-d), or (I-e)” |
| 3 |
Constrains R4 to listed options |
R4 is “phenyl” or “pyridin-4-yl”; with R4a limited to H/halo/C1-6alkyl/amino/dialkylamino |
| 4 |
Constrains R5 and R6 |
R5 = methyl, ethyl, isopropyl, tert-butyl, F/Cl/Br; R6 = methoxy |
| 5 |
Narrows R1 to ether form |
R1 = —OR7; R7 = C1-6alkyl or H |
| 6 |
Narrows R1 to sulfonamide |
R1 = —NHS(=O)2R8; R8 = methyl/cyclopropyl/phenyl |
| 7 |
Narrows sulfonamide further |
R8 = cyclopropyl substituted with methyl |
| 8-9 |
Fixes macrocycle parameter |
n = 4 or 5; claim 9 fixes n = 4 |
| 10-11 |
Fixes R3 |
R3 = H or C1-6alkyl; claim 11 narrows to H or methyl |
| 12 |
R4 hetero-attach constraints |
when possible nitrogen in R4 bears R4a; “each R4a ... is Het” |
| 13-14 |
Additional R4a list constraints; examples of radicals |
includes R4a in a set and reaffirms optional substitution on piperidinyl/morpholinyl |
| 15 |
Fixes R6 |
R6 = methoxy |
| 16-20 |
Fixes the exact “formula (I)” instantiations |
claim 16 references formula provided but text is truncated; claims 17-20 specify additional features (e.g., double bond between C7 and C8 present) |
| 21-22 |
Removes specific species |
claim 21: “other than an N-oxide, or salt”; claim 22: “other than an N-oxide” |
Net effect: Dependent claims carve out specific instantiations (exact ring sizes, named substituent sets, specific R1 variants). They do not remove Claim 1’s breadth; they help define which compositions the patentee emphasized, which matters for infringement targeting and for licensing strategy.
What therapeutic and combination claims are included?
US 8,349,869 includes three major “downstream” claim families: combinations, formulations, and methods, each tied to the same compound genus.
Combination claims
- Claim 23: compound of Claim 1 + ritonavir (or salt)
- Claim 24: compound of Claim 1 + interferon-α, pegylated interferon-α, and/or ribavirin
Formulation claims
- Claim 25: pharmaceutical composition with carrier; active ingredient is an anti-viral effective amount of compound of Claim 1
- Claim 26: pharmaceutical composition with carrier; active ingredient is an anti-viral effective amount of combination of Claim 23 or 24
Methods of use
- Claim 27: method of inhibiting HCV replication by administering compound of Claim 1
- Claim 28: method of inhibiting HCV replication by administering combination of Claim 23 or 24
Breadth note: The method claims are limited by purpose (“inhibiting HCV replication”) and by administration of the claimed compound family. The presence of ritonavir/interferon/ribavirin indicates targeting of existing HCV regimens and suggests a strategy to capture combination-based treatment practice.
What is the process/solid support scope?
US 8,349,869 also claims manufacturing routes for the same compound class.
Process claim (Claim 29)
Claim 29 recites a multi-step synthetic process to prepare compounds of Claim 1, including:
- producing an intermediate with double bond formation between C7 and C8 with concomitant cyclization to the macrocycle (compound of formula (I-i))
- converting the C7-C8 double bond to a single bond by reduction (to formula (I-j))
- installing R1 as either:
- sulfonamide (amide bond between intermediate (2a) and sulfonylamine (2b)), or
- alkoxy (ester bond between intermediate (2a) and alcohol (2c))
- nitrogen deprotection step for R3 = hydrogen
- Mitsunobu or substitution to react intermediates (4a) and (4b) based on whether Y is hydroxy or leaving group
- functional group transformations among compound variants
- salt formation by reacting free form with acid or base
Specific enhancement (Claim 30)
- Step (a) double bond formation with concomitant cyclization is via olefin metathesis.
Legal implication: Process claims can matter for lifecycle freedom-to-operate where third parties use materially different routes; they also matter for license negotiations with API manufacturers.
How does the claim language map to practical “design-around” space?
Claim 1’s breadth is driven by three axes: (1) macrocycle core flexibility (double bond optionality and n), (2) multiple substitution positions (R4-R8 are heavily enumerated), and (3) peripheral functional options at R1 (ether vs sulfonamide).
The main “claim levers” that determine whether a competitor can design around
A competitor invalidates or avoids infringement only if the target does not fall within Claim 1’s structural definitions. Based on the provided wording, the highest-risk elements for design-around are:
-
The R1 functional class
- Claim 1 explicitly includes —OR7 and —NH—SO2R8
- A competitor would need to choose a non-covered functional at the corresponding position (not an ether or sulfonamide as defined).
-
Macrocycle size parameter n
- n is limited to 3, 4, 5, or 6
- A competitor outside these values could avoid.
-
R4 aryl/Het inclusion
- R4 is aryl or Het, with broad Het substituent options
- Avoiding requires a position replacement that is not aryl/Het as defined (hard if the chemistry wants aromatic/heteroaromatic).
-
R5 and R6 enumerations
- R5 includes halo, C1-6 alkyl, hydroxy, polyhaloC1-6alkyl, phenyl, Het
- R6 is C1-6 alkoxy or dimethylamino
- Design-around likely targets these residues by choosing non-enumerated groups.
-
N-oxide and salt coverage
- Claim 1 covers “N-oxide, pharmaceutically acceptable salt, or stereoisomer thereof”
- Even if a competitor changes a salt form, they can still fall within coverage.
Where does this patent likely sit in the HCV antiviral landscape?
The claims explicitly recite HCV replication inhibition, plus combination partners that map onto established treatment backbones (ritonavir; interferon-α/pegylated interferon-α; ribavirin).
Combination strategy indicates “regimen coverage”
- Ritonavir combination (Claim 23) implies either a pharmacokinetic boosting role or a regimen co-administration practice.
- Interferon and ribavirin combination (Claim 24) covers the classic backbone used in older HCV therapy frameworks.
The patent landscape risk to generic or follow-on entrants is highest where:
- their candidate is structurally within Claim 1’s genus, and
- their intended label practice includes combination therapy consistent with Claims 23-28.
Patent landscape impact: what competitors can infer from claim drafting
Even without the rest of the patent family text, Claim 1’s structure creates a common licensing and clearance problem: broad genus claims plus enumerated dependent claims.
How this typically affects freedom-to-operate (FTO)
- Genus claim dominance: If a competitor’s molecule lies inside the Claim 1 parameter set, dependent claims often become irrelevant for infringement because Claim 1 already covers.
- Sub-genus emphasis: Dependent claims (n fixed to 4; R4 limited to phenyl or pyridin-4-yl; R5 and R6 constrained; R1 fixed to specific sulfonamides) often correlate with the patentee’s preferred embodiments and can guide how an examiner or later litigant interprets the boundaries of the genus.
- Process hooks: Olefin metathesis for the critical macrocycle-forming step (Claim 30) creates route-based infringement exposure for API suppliers using that key transformation, even if end-user formulations are not at issue.
Key Takeaways
- US 8,349,869 claim 1 is a broad genus claim covering a macrocyclic compound family with optional double bonds, variable macrocycle size parameter n (3-6), and extensive substitution at R3-R8, including aryl/Het groups and detailed phenyl/heterocycle substitution lists.
- R1 is a major inclusion gate: the claim covers ether forms (—OR7) and sulfonamide forms (—NH—SO2R8) plus stereoisomers, N-oxides, and pharmaceutically acceptable salts.
- The patent extends beyond composition into combinations (ritonavir; interferon-α/peginterferon-α and ribavirin), formulations, and methods of inhibiting HCV replication, plus multi-step synthetic processes, including an olefin metathesis route for forming the C7-C8 double bond with concomitant macrocycle cyclization.
- For competitors, the most realistic design-around pressure points are functional class at R1, macrocycle size parameter n, and enumerated substituent choices at R5/R6 and heteroaryl/aryl sets at R4.
- The claims are drafted to support both regimen practice coverage and manufacturing-route coverage, increasing enforcement leverage.
FAQs
-
Does Claim 1 cover only one molecule or many?
It covers a large genus of macrocyclic compounds defined by variable parameters (X; R1-R8; n) with optional double bonds and multiple allowed substituent classes.
-
Are N-oxides and salts within scope?
Yes. Claim 1 explicitly includes N-oxides, pharmaceutically acceptable salts, and stereoisomers.
-
Can a competitor avoid infringement by using a different salt?
Not if the underlying compound falls within Claim 1 because Claim 1 includes pharmaceutically acceptable salts.
-
Do the claims cover treatment regimens with ritonavir and interferon/ribavirin?
Yes. Claims 23-28 cover combinations and HCV replication inhibition using those agents alongside the claimed compound family.
-
Is there a route-to-infringement path for API manufacturing?
Yes. Claim 29 covers processes to make the compounds, and Claim 30 specifies that the key double bond formation with concomitant cyclization can be done via olefin metathesis.
References
[1] US Patent 8,349,869 (claims as provided in the prompt).
More… ↓
⤷ Start Trial
|
